ArticleFrontiers in immunology2026
A comprehensive study based on large-sample multi-omics integration and machine learning to decode mitochondria-associated genes: from digestive tract tumours to gastric cancer.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mitochondria-related genes play a crucial role in driving tumour cell progression, but little is known about their molecular mechanisms and biological pathways. This study conducted a comprehensive analysis of the mitochondrial key gene LACTB2 in digestive tract tumours and explored a novel early blood-based diagnostic model for gastric cancer (GC). Methods: This study analyzed LACTB2 expression, biological pathways, and immune regulation in a large cohort of 10,581 samples. IHC staining was performed using 236 internal GC samples. Multi-omics data were integrated for comprehensive analysis of LACTB2 in GC. A combination of extensive clinical samples and multiple machine learning models enabled the construction of prognostic and blood-based diagnostic models (n = 14,219). Results: LACTB2 overexpression is associated with clinical metastasis and the activation of pro-cancer pathways, and LACTB2 may mediate immune suppression and immune evasion through various methods. There is a significant transcriptional regulatory network upstream of LACTB2. LACTB2 overexpression may drive malignant transformation of GC epithelial cells through pro-cancer metabolic signalling networks, and the related mechanisms were spatially validated. Dysregulated expression of LACTB2 can affect the prognosis of GC patients, and Afatinib and Ulixertinib may play a significant role in targeting LACTB2 in the treatment of GC patients. An excellent early blood diagnostic model for GC was constructed based on the upstream miRNA of LACTB2. Conclusion: Our study provides new insights into the differential expression and pathogenesis of LACTB2 in digestive tract tumours, particularly its prognostic and diagnostic value in GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.